Phase I-/II-study of hyperfractionated-accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Oct 2016 Results (5-years) assessing feasibility, efficacy and safety of combination therapy with cisplatin, cetuximab and hyperfractionated-accelerated radiotherapy (n=74) presented at the 41st European Society for Medical Oncology Congress.
12 Jul 2011 Additional trial identifiers (EudraCT2005-000355-15, KKSH19) identified, trial status is recruiting, planned patient patient number is 74 as reported by European Clinical Trials Database.
12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000355-15)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com